| ¡@ |
|
PAC-LINK BioVentures
participated in GlobeImmune,
Inc. Series B financing. |
|
10/01/2004 |
|
|
In Oct. 2005, PAC-LINK
BioVentures participated in
GlobeImmune, Inc., Series B
financing, which was led by
Lilly Ventures and also included
HealthCare Ventures,
Morgenthaler Ventures, Sequel
Venture Partners, Medica Venture
Partners, Adams Street Partners,
Biogen Idec, Inc., Genentech,
Inc., Partners Healthcare, GC&H
Investments, China Investment
and Development (CIDC) and
Yasuda Enterprise Development.
GlobeImmune, Inc., is a
biopharmaceutical company
pioneering the discovery,
development and manufacturing of
potent, targeted molecular
immunotherapy products called
Tarmogens TM for the treatment
of cancer and infectious
diseases. GlobeImmune plans to
use the Series B funds to
complete a placebo-controlled
Phase 2 clinical trial of
GI-4000 in patients with
pancreatic cancer as well as
complete a placebo-controlled
Phase 1b clinical trial of
GI-5005 in patients with chronic
hepatitis C infection. |
| ¡@ |
¡@ |
¡@ |
